FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Rosiglitazone will be available under a Risk Evaluation and Mitigation Strategy with restricted distribution pending an independent panel's re-adjudication of CV endpoints in the much-maligned, open-label RECORD study.